MVC’s WHO-Partnered Vaccine a First for Taiwan
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
Address:
Tel: 886-2-2655-8133
In view of the need for an inter-agency task to carry out the promotion of the biotechnology and pharmaceutical high-tech industries, in November 1995 the Executive Yuan approved the key points for establishing the Biotechnology and Pharmaceutical Industries Program Office (BPIPO, MOEA). In February 1996 the BPIPO was formerly established to implement and promote the biotechnology industry’s development policy and act as a bridge for communication, coordination and integration among agencies. In December 2001, The Executive Yuan’s One-Stop-Service Office for the Biotechnology Industry was established under the BPIPO, with the office being responsible for the integration and coordination of local organizations involved in the various biotech-related approval and application processes, to build up a sound development environment for the biotech industry. The Director of the Industrial Development Bureau, MOEA acted as convener of the Program Office and formed a committee including the heads of the Executive Yuan’s Department of Health; Environmental Protection Administration; Council for Economic Planning and Development; National Science Council; Council of Agriculture; Science & Technology Advisory Group (STAG); Committee for the Development Fund; Department of Industrial Technology, MOEA; Intellectual Property Office, MOEA; and related government agencies; and representatives, academics, and experts from major research organizations and industry to form an inter-agency promotional organization.
The role of the Program Office is to serve as a window for the exchange of vital information between domestic and foreign industry, and to aggressively promote investment in Taiwan. In so doing, the Program Office hopes to accelerate the upgrading of Taiwan’s biotechnology and pharmaceutical industries and promote Taiwan to become an R&D, manufacturing and operations center for the Asia Pacific region, and furthermore to forge ahead to establish a global operations center.
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
In an important milestone for Taiwan’s biotech industry, Diamond Biofund – one of the territory’s most well-established venture capital (VC) funds – became the first such firm to list on…
The latest pharma news from Taiwan, including Gongwin-KY’s lung cancer drug approval in China, Anxo Pharmaceutical/Genovior Biotech alliance, Taiwan’s Industrial Technology Research Institute (ITRI) and Metagone Biotech’s glaucoma and macular…
The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed,…
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s rapid and coordinated response to the COVID-19 crisis and also explains how Quark Biosciences’ diagnostics and precision…
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that is the envy of its neighbours. Here, three country managers for…
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an enviable reputation at the forefront of some of the most innovative trends shaping global…
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market, rising medical needs in Asia are helping foster more regionally-focused strategies. …
All country managers of multinational pharma companies need to strike the balance between having a global outlook and adapting to local culture. For BoonHuey Ee, general manager of Merck Biopharma…
See our Cookie Privacy Policy Here
